Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) Wells Fargo 2024 Healthcare Conference
Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.
Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Becton, Dickinson and Company (BDX) Q3 2024 Earnings Call Transcript
Becton, Dickinson and Company (NYSE:BDX ) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Rick Wise - Stifel Vijay Kumar - Evercore ISI Operator Hello and welcome to BD's Third Quarter Fiscal 2024 Earnings Conference Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at investors.bd.com or by phone at 800-839-2385 for domestic calls and area code +1 402-220-7203 for international calls.
Compared to Estimates, Becton Dickinson (BDX) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago.
Becton Dickinson tops profit estimates on demand for drug-delivery devices
Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
